[go: up one dir, main page]

EA200200819A1 - Кристаллическая форма ii линезолида - Google Patents

Кристаллическая форма ii линезолида

Info

Publication number
EA200200819A1
EA200200819A1 EA200200819A EA200200819A EA200200819A1 EA 200200819 A1 EA200200819 A1 EA 200200819A1 EA 200200819 A EA200200819 A EA 200200819A EA 200200819 A EA200200819 A EA 200200819A EA 200200819 A1 EA200200819 A1 EA 200200819A1
Authority
EA
Eurasian Patent Office
Prior art keywords
linezolide
crystal form
linezolid
published
useful
Prior art date
Application number
EA200200819A
Other languages
English (en)
Other versions
EA004434B1 (ru
Inventor
Майкл С. Бергрен
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22658183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200200819(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200200819A1 publication Critical patent/EA200200819A1/ru
Publication of EA004434B1 publication Critical patent/EA004434B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новой кристаллической форме (Форма II) известного соединения, линезолида, которое является полезным в качестве антибактериального средства.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200819A 2000-02-02 2001-01-29 Кристаллическая форма ii линезолида EA004434B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17983700P 2000-02-02 2000-02-02
PCT/US2001/000657 WO2001057035A1 (en) 2000-02-02 2001-01-29 Linezolid-crystal form ii

Publications (2)

Publication Number Publication Date
EA200200819A1 true EA200200819A1 (ru) 2003-02-27
EA004434B1 EA004434B1 (ru) 2004-04-29

Family

ID=22658183

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200819A EA004434B1 (ru) 2000-02-02 2001-01-29 Кристаллическая форма ii линезолида

Country Status (30)

Country Link
EP (1) EP1255754B1 (ru)
JP (1) JP5235256B2 (ru)
KR (3) KR100864745B1 (ru)
CN (1) CN1221547C (ru)
AR (1) AR027261A1 (ru)
AT (1) ATE297920T1 (ru)
AU (1) AU782138B2 (ru)
BR (1) BR0107667A (ru)
CA (1) CA2395603C (ru)
CO (1) CO5261555A1 (ru)
CZ (1) CZ302292B6 (ru)
DE (1) DE60111497T2 (ru)
DK (1) DK1255754T3 (ru)
EA (1) EA004434B1 (ru)
EE (1) EE05197B1 (ru)
ES (1) ES2242728T3 (ru)
HU (1) HUP0301076A3 (ru)
IL (1) IL151010A0 (ru)
MX (1) MXPA02007471A (ru)
MY (1) MY122829A (ru)
NO (2) NO323459B1 (ru)
NZ (1) NZ520541A (ru)
PE (1) PE20011086A1 (ru)
PL (1) PL356433A1 (ru)
PT (1) PT1255754E (ru)
SI (1) SI1255754T1 (ru)
SK (1) SK287025B6 (ru)
TW (1) TWI297687B (ru)
WO (1) WO2001057035A1 (ru)
ZA (1) ZA200205162B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490643B1 (ko) * 2002-10-29 2005-05-19 한국과학기술연구원 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법
EP2902386B1 (en) 2003-10-16 2020-04-08 Symed Labs Limited A crystalline form of linezolid
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
EP2174935A1 (en) * 2004-06-29 2010-04-14 Teva Pharmaceutical Industries Ltd Linezolid Compositions
CA2572207A1 (en) * 2004-06-29 2006-10-19 Teva Pharmaceutical Industries Ltd. Solid forms of linezolid and processes for preparation thereof
US7291614B2 (en) 2005-02-24 2007-11-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
EP1893195A2 (en) * 2005-06-22 2008-03-05 Teva Pharmaceutical Industries Ltd Polymorphic forms of tegaserod maleate
US20070020329A1 (en) * 2005-07-20 2007-01-25 Ruth Tenengauzer Methods of formulating linezolid
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2011050826A1 (en) 2009-10-28 2011-05-05 Synthon B.V. Process for making crystalline form a of linezolid
MX2012012627A (es) 2010-04-30 2013-05-09 Univ Indiana Res & Tech Corp Proceso para preparar linezolid.
EP2603505A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
EP2593440A1 (en) * 2011-02-24 2013-05-22 Lee Pharma Limited Anhydrous linezolid crystalline form-ii
WO2012119653A1 (en) 2011-03-09 2012-09-13 Synthon Bv Process for making crystalline form a of linezolid
CN102731341A (zh) * 2011-04-13 2012-10-17 上海医药工业研究院 用于制备利奈唑胺的中间体及其制备方法
CN102766106A (zh) * 2011-05-03 2012-11-07 江苏豪森医药集团有限公司 利奈唑胺的新晶型及其制备方法
CN102399200B (zh) * 2011-12-14 2013-12-04 浙江新东港药业股份有限公司 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法
EP2852580A1 (en) 2012-01-24 2015-04-01 Jubilant Life Sciences Ltd. Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
CN102643245A (zh) * 2012-04-10 2012-08-22 杭州华东医药集团生物工程研究所有限公司 一种利奈唑胺晶型及其制备方法
EP2917189B1 (en) 2012-11-09 2016-08-17 Synthon BV Process for making linezolid
KR102615354B1 (ko) 2016-11-16 2023-12-21 페르시카 파마슈티컬스 리미티드 요통을 위한 항생제 제형
AU2018369696B2 (en) * 2017-11-16 2024-02-01 Persica Pharmaceuticals Ltd. Linezolid formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1997037980A1 (en) * 1996-04-11 1997-10-16 Pharmacia & Upjohn Company Process to prepare oxazolidinones
PL199355B1 (pl) * 1997-11-07 2008-09-30 Upjohn Co Drugorzędowy (S)-alkohol i sposób jego wytwarzania oraz sposób wytwarzania (S)-3-karboaminoalkoholu

Also Published As

Publication number Publication date
SI1255754T1 (sl) 2005-12-31
NO20023654D0 (no) 2002-08-01
NO20065836L (no) 2002-08-01
DE60111497D1 (de) 2005-07-21
KR20020072300A (ko) 2002-09-14
EE05197B1 (et) 2009-08-17
PE20011086A1 (es) 2001-10-04
SK287025B6 (sk) 2009-10-07
AR027261A1 (es) 2003-03-19
AU3275501A (en) 2001-08-14
WO2001057035A1 (en) 2001-08-09
ES2242728T3 (es) 2005-11-16
PT1255754E (pt) 2005-11-30
JP5235256B2 (ja) 2013-07-10
CN1221547C (zh) 2005-10-05
ZA200205162B (en) 2003-09-29
JP2003522175A (ja) 2003-07-22
NZ520541A (en) 2004-02-27
ATE297920T1 (de) 2005-07-15
CA2395603A1 (en) 2001-08-09
KR100781815B1 (ko) 2007-12-03
EE200200420A (et) 2003-12-15
HK1051196A1 (en) 2003-07-25
KR20070087178A (ko) 2007-08-27
AU782138B2 (en) 2005-07-07
MY122829A (en) 2006-05-31
HUP0301076A3 (en) 2004-06-28
CN1394207A (zh) 2003-01-29
EP1255754A1 (en) 2002-11-13
TWI297687B (en) 2008-06-11
EA004434B1 (ru) 2004-04-29
NO20023654L (no) 2002-08-01
SK9942002A3 (en) 2002-11-06
EP1255754B1 (en) 2005-06-15
CZ20022635A3 (cs) 2002-10-16
MXPA02007471A (es) 2002-12-13
PL356433A1 (en) 2004-06-28
NO323459B1 (no) 2007-05-14
IL151010A0 (en) 2003-02-12
CA2395603C (en) 2010-03-23
CZ302292B6 (cs) 2011-02-09
DE60111497T2 (de) 2006-05-18
DK1255754T3 (da) 2005-08-22
HUP0301076A2 (hu) 2003-08-28
KR100864745B1 (ko) 2008-10-22
BR0107667A (pt) 2002-10-08
CO5261555A1 (es) 2003-03-31
KR20080044358A (ko) 2008-05-20

Similar Documents

Publication Publication Date Title
EA200200819A1 (ru) Кристаллическая форма ii линезолида
EA200300107A1 (ru) Кристаллические формы трет-бутиламиновой соли периндоприла
DK1385515T3 (da) Spiropyrazole forbindelser
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
EA200101232A1 (ru) Соединения феноксипропиламина
DK1485359T3 (da) Natriumkanalblokkere
CY1113362T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
BR9900177A (pt) Inibidores de metaloprotease.
EA200401157A1 (ru) N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
NO20003111D0 (no) Ortho-anthranilamidderivater som antikoagulanter
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
TR200001876T2 (tr) HIV proteaz inhibitörünün bisülfat tuzu.
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
EA200100757A1 (ru) Хинолинкарбоксамиды в качестве противовирусных агентов
PT1307455E (pt) Inibidores de adesao celular mediada por (alfa)l (beta)2
SE0100903D0 (sv) Compounds
EA200200699A1 (ru) Оксазолидиноны, обладающие сульфоксиминовой функциональностью
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
SE0103710D0 (sv) Compounds
EA200200673A1 (ru) Оксазолидиноновые эфиры бензойной кислоты, содержащие гидроксиацетилпиперазиновый заместитель
EA200300988A1 (ru) Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина
BR0115996A (pt) Sulfamidotienopirimidinas
EA200300520A1 (ru) Способ получения кристаллического моногидрата n-формимидоилтиенамицина (моногидрата имипенема)
BRPI0416678A (pt) pirazolpirimidinas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU